In a blow to Johnson & Johnson, the company was ordered last Friday to pay $70 million to a male Tennessee teenager who claimed its Risperdal antipsychotic pill caused him to grow enlarged breasts. The finding by a Pennsylvania state court jury was not only the latest, but it is the biggest defeat to date in what has become another sprawling litigation over the drug.

In reaching its decision, the jury found that J&J failed to properly warn Risperdal could cause gynecomastia, which is the abnormal development of large mammary glands in males. Moreover, the jury also determined that the company “intentionally falsified, destroyed, or concealed records” that Risperdal could cause boys to develop breasts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am preparing for a Tedx Talk and came across this article.
    Risperdal was approved in 1993 for schizophrenia, not 2002. It was the first of the new second-generation antipsychotics. I know because I was the medical ad writer on it between 1996-1998.

    “The cases have garnered attention for a couple of reasons. For one, J&J has a bad track record when it comes to marketing Risperdal, which was first approved in 2002 to treat schizophrenia.”

    Lydia

    The cases have garnered attention for a couple of reasons. For one, J&J has a bad track record when it comes to marketing Risperdal, which was first approved in 2002 to treat schizophrenia.

    • Hi Lydia,

      Thanks for the note.

      The FDA first approved the drug in 1993 to manage symptoms of psychiatric disorders and the labeling was revised in 2002 more specifically for treating schizophrenia. So I’ve updated the story to reflect that.

      Regards
      ed at pharmalot

  • I think that J&J knew what they was doing it was all about money with them so I think they need to pay the cause pain in people families in-life

  • I want too see the ceo put in prison for poisoning me with risperdal and now I live with a deformity and think of ending my suffering daily please help me and other victims will

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy